AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Apogee Therapeutics to Present at Stifel 2025 Virtual Immunology and Inflammation Forum
ByAinvest
Wednesday, Sep 3, 2025 7:32 am ET1min read
Apogee Therapeutics announced its participation in the Stifel 2025 Virtual Immunology and Inflammation Forum, where management will participate in a fireside chat on September 16, 2025. The company's most advanced program, APG777, is being developed for the treatment of Atopic Dermatitis. Apogee's pipeline includes four validated targets and aims to deliver value and benefit to patients underserved by today's standard of care.
Apogee Therapeutics, Inc. (Nasdaq: APGE) has announced its participation in the Stifel 2025 Virtual Immunology and Inflammation Forum. The company's management team will engage in a fireside chat scheduled for Tuesday, September 16, 2025, at 11:30 a.m. E.T. [1]The fireside chat will provide investors and interested parties with an opportunity to hear directly from Apogee's leadership about the company's progress and future plans. A live and archived webcast of the event will be available via the News & Events page in the Investors section of Apogee Therapeutics' website.
Apogee Therapeutics is a clinical-stage biotechnology company focused on developing optimized, novel biologics for various indications, including Atopic Dermatitis (AD), asthma, Eosinophilic Esophagitis (EoE), and Chronic Obstructive Pulmonary Disease (COPD). The company's most advanced program, APG777, is being initially developed for the treatment of AD, one of the largest and least penetrated markets in the immune and inflammatory (I&I) space. Apogee's pipeline includes four validated targets, with the aim of delivering best-in-class profiles through monotherapies and combinations of its novel antibodies. [1]
The company's approach involves targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. By doing so, Apogee Therapeutics seeks to provide meaningful benefits to patients currently underserved by existing therapies. [1]
For more information about Apogee Therapeutics and its upcoming events, please visit their website at [https://apogeetherapeutics.com](https://apogeetherapeutics.com). Investor inquiries can be directed to Noel Kurdi, VP, Investor Relations, at [noel.kurdi@apogeetherapeutics.com](mailto:noel.kurdi@apogeetherapeutics.com). [1]
References:
[1] https://www.stocktitan.net/news/APGE/apogee-therapeutics-to-participate-at-the-stifel-2025-virtual-67s3kws5qpr5.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet